Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Overexpression of p73 enhances cisplatin-induced apoptosis in HeLa cells

Overexpression of p73 enhances cisplatin-induced apoptosis in HeLa cells To examine a possible synergistic role for p73 and cisplatin ( cis -diamminedichloroplatinum II) in HeLa cells with a nonfunctional p53 protein, we established stable HeLa/p73 clones using a tetracycline inducible eukaryotic expression vector. The HeLa/p73 clones were not characterized by changes in growth or morphology. Cell death analysis, however, indicated a greater sensitivity to cisplatin in the p73-overexpressed HeLa cells than determined for the non-induced HeLa cells. This increased sensitivity seems to affect an induction of a sub-G1 population as assessed from flow cytometry analysis. The increased sub-G1 population may, in turn, result from a reduction of cyclin D1 and B1 expression by cisplatin in the presence of p73. Hoechest staining indicated an increased number of dead cells in the p73-induced cells compared to the non-induced cells. Poly ADP-ribose polymerase (PARP) cleavage was shown to be distinct in the p73-overexpressed cells compared to non-induced cells, which suggests that p73 modulates the cisplatin-induced apoptosis. Therefore, a synergistic effect of p73 and cisplatin to induce apoptosis could lead to new treatment for some types of human cancers. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Pharmacal Research Springer Journals

Overexpression of p73 enhances cisplatin-induced apoptosis in HeLa cells

Loading next page...
 
/lp/springer-journals/overexpression-of-p73-enhances-cisplatin-induced-apoptosis-in-hela-m1ixR2WJ0F

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2006 by The Pharmaceutical Society of Korea
Subject
Pharmacy; Pharmacy; Pharmacology/Toxicology
ISSN
0253-6269
eISSN
1976-3786
DOI
10.1007/BF02974277
Publisher site
See Article on Publisher Site

Abstract

To examine a possible synergistic role for p73 and cisplatin ( cis -diamminedichloroplatinum II) in HeLa cells with a nonfunctional p53 protein, we established stable HeLa/p73 clones using a tetracycline inducible eukaryotic expression vector. The HeLa/p73 clones were not characterized by changes in growth or morphology. Cell death analysis, however, indicated a greater sensitivity to cisplatin in the p73-overexpressed HeLa cells than determined for the non-induced HeLa cells. This increased sensitivity seems to affect an induction of a sub-G1 population as assessed from flow cytometry analysis. The increased sub-G1 population may, in turn, result from a reduction of cyclin D1 and B1 expression by cisplatin in the presence of p73. Hoechest staining indicated an increased number of dead cells in the p73-induced cells compared to the non-induced cells. Poly ADP-ribose polymerase (PARP) cleavage was shown to be distinct in the p73-overexpressed cells compared to non-induced cells, which suggests that p73 modulates the cisplatin-induced apoptosis. Therefore, a synergistic effect of p73 and cisplatin to induce apoptosis could lead to new treatment for some types of human cancers.

Journal

Archives of Pharmacal ResearchSpringer Journals

Published: Feb 1, 2006

There are no references for this article.